

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (empagliflozin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Pumping Marvellous Foundation <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Society for Heart Failure • Primary Care Cardiovascular Society • Royal College of Physicians • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (furosemide) (confidentiality agreement not signed, not participating) • ADVANZ Pharma (furosemide) (confidentiality agreement not signed, not participating) • AstraZeneca (dapagliflozin) • Baxter Healthcare (furosemide) (confidentiality agreement not signed, not participating) • Hameln Pharmaceuticals (furosemide) (confidentiality agreement not signed, not participating) • Ipca Laboratories UK (furosemide) (confidentiality agreement not signed, not participating) • Mylan (bumetanide, torasemide) (confidentiality agreement not signed, not participating)

Final Stakeholder list for the single technology appraisal of empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945].

Issue date: July 2022

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Pinewood Healthcare (furosemide) (confidentiality agreement not signed, not participating) • Rosemont Pharmaceuticals (furosemide) (confidentiality agreement not signed, not participating) • Thame Laboratories (furosemide) (confidentiality agreement not signed, not participating) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • <i>None</i> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • <i>None</i>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.